Cargando…
Re: ‘Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis’ by Tleyjeh et al.
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862016/ https://www.ncbi.nlm.nih.gov/pubmed/33549765 http://dx.doi.org/10.1016/j.cmi.2021.01.025 |
_version_ | 1783647196413952000 |
---|---|
author | Koeckerling, David Pan, Daniel Barker, Joseph |
author_facet | Koeckerling, David Pan, Daniel Barker, Joseph |
author_sort | Koeckerling, David |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-7862016 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78620162021-02-05 Re: ‘Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis’ by Tleyjeh et al. Koeckerling, David Pan, Daniel Barker, Joseph Clin Microbiol Infect Letter to the Editor European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2021-08 2021-02-05 /pmc/articles/PMC7862016/ /pubmed/33549765 http://dx.doi.org/10.1016/j.cmi.2021.01.025 Text en © 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Letter to the Editor Koeckerling, David Pan, Daniel Barker, Joseph Re: ‘Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis’ by Tleyjeh et al. |
title | Re: ‘Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis’ by Tleyjeh et al. |
title_full | Re: ‘Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis’ by Tleyjeh et al. |
title_fullStr | Re: ‘Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis’ by Tleyjeh et al. |
title_full_unstemmed | Re: ‘Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis’ by Tleyjeh et al. |
title_short | Re: ‘Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis’ by Tleyjeh et al. |
title_sort | re: ‘efficacy and safety of tocilizumab in covid-19 patients: a living systematic review and meta-analysis’ by tleyjeh et al. |
topic | Letter to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862016/ https://www.ncbi.nlm.nih.gov/pubmed/33549765 http://dx.doi.org/10.1016/j.cmi.2021.01.025 |
work_keys_str_mv | AT koeckerlingdavid reefficacyandsafetyoftocilizumabincovid19patientsalivingsystematicreviewandmetaanalysisbytleyjehetal AT pandaniel reefficacyandsafetyoftocilizumabincovid19patientsalivingsystematicreviewandmetaanalysisbytleyjehetal AT barkerjoseph reefficacyandsafetyoftocilizumabincovid19patientsalivingsystematicreviewandmetaanalysisbytleyjehetal |